Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

NCT03281681 is registered in ClinicalTrials.gov with DelMar Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03281681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03281681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
Lead sponsor
DelMar Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
March 31, 2021
Completion date
September 30, 2022
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer